Dry eye disease (DED) is a common disorder of the tears and ocular surface, affecting some 5 million Americans 50 years of age and older and affecting women disproportionately. 1 Tens of millions more have less severe symptoms typically triggered by adverse factors such as low humidity or contact lens wear. 1 Although the disorder is not life threatening, the symptoms of pain and irritation associated with DED significantly impede daily activities such as driving and reading and reduce overall quality of life. 2 The prominent role of inflammation in the development and exacerbation of DED is well recognized, but our understanding of the pathogenesis of DED is far from complete. 2 This has hindered the development of novel treatments, with Restasis remaining the only Food and Drug Administration-approved dry eye pharmaceutical treatment in the United States.
